Table 2.

Risk of conventional adenomas and SPs during follow-up (years 2–4) associated with categories of circulating serum high-sensitivity CRP levels

CrudeAdjusteda
CRP levelsEvents/N (%)RR (95% CI)RR (95% CI)
All adenomas
 Dichotomous
  ≤Median121/337 (35.9%)1.00 (REF.)1.00 (REF.)
  >Median126/335 (37.6%)1.05 (0.86–1.28)0.99 (0.80–1.21)
 Quartiles
  Q1: ≤0.74 mg/L55/164 (33.5%)1.00 (REF.)1.00 (REF.)
  Q2: 0.74–1.785 mg/L66/173 (38.2%)1.14 (0.86–1.51)1.11 (0.83–1.49)
  Q3: 1.785–3.90 mg/L66/169 (39.1%)1.16 (0.88–1.55)1.09 (0.82–1.46)
  Q4: >3.90 mg/L60/166 (36.1%)1.08 (0.80–1.44)0.99 (0.73–1.34)
Advanced neoplasmsb
 Dichotomous
  ≤Median30/330 (9.1%)1.00 (REF.)1.00 (REF.)
  >Median36/325 (11.1%)1.22 (0.77–1.93)0.98 (0.62–1.55)
 Quartiles
  Q1: ≤0.74 mg/L16/162 (9.9%)1.00 (REF.)1.00 (REF.)
  Q2: 0.74–1.785 mg/L14/168 (8.3%)0.84 (0.43–1.67)0.85 (0.43–1.67)
  Q3: 1.785–3.90 mg/L17/164 (10.4%)1.05 (0.55–2.01)0.89 (0.47–1.70)
  Q4: >3.90 mg/L19/161 (11.8%)1.19 (0.63–2.25)0.92 (0.49–1.75)
SPs
 Dichotomous
  ≤Median69/343 (20.1%)1.00 (REF.)1.00 (REF.)
  >Median75/346 (21.7%)1.08 (0.81–1.44)1.10 (0.81–1.48)
 Quartiles
  Q1: ≤0.74 mg/L32/167 (19.2%)1.00 (REF.)1.00 (REF.)
  Q2: 0.74–1.785 mg/L37/176 (21.0%)1.10 (0.72–1.67)1.19 (0.77–1.84)
  Q3: 1.785–3.90 mg/L35/173 (20.2%)1.06 (0.69–1.62)1.10 (0.71–1.71)
  Q4: >3.90 mg/L40/173 (23.1%)1.21 (0.80–1.83)1.32 (0.85–2.03)
Proximal SPs
 Dichotomous
  ≤Median24/343 (7.0%)1.00 (REF.)1.00 (REF.)
  >Median23/346 (6.7%)0.95 (0.55–1.65)1.00 (0.59–1.71)
 Quartiles
  Q1: ≤0.74 mg/L11/167 (6.6%)1.00 (REF.)1.00 (REF.)
  Q2: 0.74–1.785 mg/L13/176 (7.4%)1.12 (0.52–2.44)1.17 (0.55–2.48)
  Q3: 1.785–3.90 mg/L11/173 (6.4%)0.97 (0.43–2.17)1.01 (0.46–2.22)
  Q4: >3.90 mg/L12/173 (6.9%)1.05 (0.48–2.33)1.19 (0.54–2.58)

Abbreviation: Q, quartile.

  • aAdjusted for treatment arm, age, sex, center, baseline adenoma history, and surveillance colonoscopy interval; RRs obtained by GLM with Poisson distribution.

  • bAdvanced neoplasm defined as an adenoma ≥10 mm, and/or with villous histology, or high-grade dysplasia/cancer.